Saturday, October 3, 2026

Dollar Index Climbs 0.1% From Three-Year Low as Multi-Year Decline Pauses

The Bloomberg Dollar Spot Index rose 0.1% after hitting its lowest level since 2022, potentially halting a slide that saw the greenback drop 14% against the euro and 7% against sterling in 2025. The reversal comes as traders reassess positioning amid shifting Federal Reserve rate expectations and geopolitical developments including Iran-US nuclear negotiations.

ViaNews Editorial Team

February 24, 2026

Source Trace Score3 source documents3 with a live linkVerifiability: Strong
Dollar Index Climbs 0.1% From Three-Year Low as Multi-Year Decline Pauses
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

The Bloomberg Dollar Spot Index gained 0.1% after touching its lowest point since 2022, signaling a possible pause in the greenback's sharp 2025 decline. The dollar fell 14% against the euro and 7% against the British pound through early 2025 as markets priced in Federal Reserve rate cuts while European central banks maintained tighter policy than expected.

Currency volatility returned to global forex markets as traders repositioned after months of dollar shorts. The pound traded at $1.3086, down 0.5% from recent highs, while the euro stood at €1.13 against sterling. Simon Phillips of No1 Currency noted sterling remains under pressure despite year-to-date gains.

Geopolitical factors are complicating currency forecasts across major markets. Progress in Iran-US nuclear deal talks could shift risk sentiment globally, while the upcoming 2026 Federal Reserve leadership transition creates policy uncertainty. Jordan Rochester at Mizuho Bank warned the pound could fall below $1.30 if dollar strength persists.

UK gilt yields climbed 4 basis points to 5.21% for 30-year bonds, the highest since August 1998, pressuring sterling as investors demand higher premiums for British debt. Neil Wilson of Saxo Markets cited fiscal instability risks. Higher yields make dollar assets relatively more attractive to international investors.

Commodity currencies face headwinds from the dollar rebound. WTI crude held near $61 per barrel, but a stronger dollar typically pressures energy markets by raising costs for buyers using other currencies. This dynamic affects oil-importing nations across Asia, Europe and Latin America.

European equity markets advanced despite forex volatility, with the Stoxx 600 reaching a record 583.4 points. The divergence between currency and equity performance suggests investors are separating regional growth prospects from short-term forex swings.

The dollar's 0.1% gain from multi-year lows creates technical support levels that could attract momentum buyers. However, mixed economic data and central bank policy divergence across major economies mean sustained dollar strength remains uncertain.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score3 source documents3 with a live linkVerifiability: Strong
  1. [1]News articleUk· November 12, 2025
    Pound hits two-year low against euro as Starmer under fire
  2. [2]News articleYahoo Finance· December 31, 2025
    Stock market today: Dow, S&P 500, Nasdaq post double-digit gains in 2025 as AI trade powers market once again
  3. [3]News articleYahoo Finance· February 17, 2026
    Stock market today: Dow, S&P 500, Nasdaq waver in volatile trading as AI anxiety lingers

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com